Zydus Lifesciences Q3 FY24 PAT up 26.8%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Global TB incidence saw a reduction of 8.7% while in India we were able to demonstrate a reduction of 16%, almost double the pace
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Additionally, an MoU was signed between the Dental Council of India and Quality Council of India for the assessment and rating of undergraduate dental colleges
Unichem Laboratories has reported total income of Rs. 445.65 crores during the period ended December 31, 2023
Sun Pharma Advanced Research Company has reported total income of Rs. 20.25 crores during the period ended December 31, 2023
RPG Life Sciences Limited has reported total income of Rs. 155.62 crores during the period ended December 31, 2023
TTK Healthcare has reported total income of Rs. 199.75 crores during the period ended December 31, 2023
KIMS has reported total income of Rs. 609.091 crores during the period ended December 31, 2023
Delivers keynote address at the 4th convocation of AIIMS Jodhpur
Abbott India has reported total income of Rs. 1492.75 crores during the period ended December 31, 2023
Thyrocare Technologies has reported total income of Rs. 137.47 crores during the period ended December 31, 2023
Dr. Lal Path Labs has reported total income of Rs. 557.2 crores during the period ended December 31, 2023
Subscribe To Our Newsletter & Stay Updated